Enfusion, Inc. (NYSE:ENFN) Receives Consensus Recommendation of “Reduce” from Brokerages

Enfusion, Inc. (NYSE:ENFN) has received an average rating of “Reduce” from the seven analysts that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.25.

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus boosted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday. Finally, Piper Sandler upped their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd.

Enfusion Price Performance

Shares of ENFN opened at $10.97 on Friday. The firm has a market capitalization of $1.41 billion, a PE ratio of 274.19, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95. Enfusion has a 1-year low of $7.52 and a 1-year high of $11.38. The company’s fifty day moving average price is $10.25 and its 200-day moving average price is $9.26.

Insider Activity

In other news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the sale, the chief financial officer now owns 266,369 shares in the company, valued at $2,698,317.97. This trade represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,041 shares of company stock worth $597,367 in the last ninety days. Company insiders own 36.44% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System purchased a new position in Enfusion in the 2nd quarter valued at about $86,000. Harbor Capital Advisors Inc. lifted its stake in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new position in Enfusion in the 3rd quarter valued at about $114,000. Paloma Partners Management Co purchased a new position in Enfusion in the 3rd quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares in the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.